Therapeutic applications of morpholino oligonucleotides

Gene and Cell Therapy: Therapeutic Mechanisms and Strategies, Fourth Edition

Volumn , Issue , 2015, Pages 521-541

  Soto Pantoja, David R ^a   Isenberg, Jeffrey S ^b   Roberts, David D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85009115942     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b18002     Document Type: Chapter

References (261)

1. Fire, A. et al., Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature, 1998. 391(6669): 806-811.
2. DiGiusto, D.L. et al., RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med, 2010. 2(36): 36ra43.
3. Xiang, S., J. Fruehauf, and C.J. Li, Short hairpin RNA-expressing bacteria elicit RNA interference in mammals. Nat Biotechnol, 2006. 24(6): 697-702.
4. Que, Q. and R.A. Jorgensen, Homology-based control of gene expression patterns in transgenic petunia flowers. Dev Genet, 1998. 22(1): 100-109.
5. Elbashir, S.M. et al., Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 2001. 411(6836): 494-498.
6. Dang, Y. et al., RNA interference in fungi: Pathways, functions, and applications. Eukaryot Cell, 2011. 10(9): 1148-1155.
7. Shabalina, S.A. and E.V. Koonin, Origins and evolution of eukaryotic RNA interference. Trends Ecol Evol, 2008. 23(10): 578-587.
8. Cerutti, H. and J.A. Casas-Mollano, On the origin and functions of RNA-mediated silencing: From protists to man. Curr Genet, 2006. 50(2): 81-99.
9. Joshua-Tor, L. and G.J. Hannon, Ancestral roles of small RNAs: An Ago-centric perspective. Cold Spring Harb Perspect Biol, 2011. 3(10): a003772.
10. Lau, N.C., Small RNAs in the animal gonad: Guarding genomes and guiding development. Int J Biochem Cell Biol, 2010. 42(8): 1334-1347.
11. Sidahmed, A.M. and B. Wilkie, Endogenous antiviral mechanisms of RNA interference: A comparative biology perspective. Methods Mol Biol, 2010. 623: 3-19.
12. Snead, N.M. and J.J. Rossi, Biogenesis and function of endogenous and exogenous siRNAs. Wiley Interdiscip Rev RNA, 2010. 1(1): 117-131.
13. Stram, Y. and L. Kuzntzova, Inhibition of viruses by RNA interference. Virus Genes, 2006. 32(3): 299-306.
14. Gavrilov, K. and W.M. Saltzman, Therapeutic siRNA: Principles, challenges, and strategies. Yale J Biol Med, 2012. 85(2): 187-200.
15. Finnegan, E.F. and A.E. Pasquinelli, MicroRNA biogenesis: Regulating the regulators. Crit Rev Biochem Mol Biol, 2013. 48(1): 51-68.
16. Graves, P. and Y. Zeng, Biogenesis of mammalian microR-NAs: A global view. Genomics Proteomics Bioinform, 2012. 10(5): 239-245.
17. Yang, J.S., T. Maurin, and E.C. Lai, Functional parameters of Dicer-independent microRNA biogenesis. RNA, 2012. 18(5): 945-957.
18. Cullen, B.R., Derivation and function of small interfering RNAs and microRNAs. Virus Res, 2004. 102(1): 3-9.
19. Wilson, R.C. and J.A. Doudna, Molecular mechanisms of RNA interference. Annu Rev Biophys, 2013. 42: 217-239.
20. Ender, C. and G. Meister, Argonaute proteins at a glance. J Cell Sci, 2010. 123(Pt 11): 1819-1823.
21. Betancur, J.G., M. Yoda, and Y. Tomari, miRNA-like duplexes as RNAi triggers with improved specificity. Front Genet, 2012. 3: 127.
22. Elbashir, S.M., W. Lendeckel, and T. Tuschl, RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev, 2001. 15(2): 188-200.
23. Braun, J.E., E. Huntzinger, and E. Izaurralde, A molecular link between miRISCs and deadenylases provides new insight into the mechanism of gene silencing by microRNAs. Cold Spring Harb Perspect Biol, 2012. 4(12).
24. Schirle, N.T. and I.J. MacRae, The crystal structure of human Argonaute2. Science, 2012. 336(6084): 1037-1040.
25. Elkayam, E. et al., The structure of human argonaute-2 in complex with miR-20a. Cell, 2012. 150(1): 100-110.
26. Kuhn, C.D. and L. Joshua-Tor, Eukaryotic Argonautes come into focus. Trends Biochem Sci, 2013. 38(5): 263-271.
27. De, N. et al., Highly complementary target RNAs promote release of guide RNAs from human Argonaute2. Mol Cell, 2013. 50(3): 344-355.
28. Frohn, A. et al., Dicer-dependent and -independent Argonaute2 protein interaction networks in mammalian cells. Mol Cell Proteomics, 2012. 11(11): 1442-1456.
29. Yao, B., S. Li, and E.K. Chan, Function of GW182 and GW bodies in siRNA and miRNA pathways. Adv Exp Med Biol, 2013. 768: 71-96.
30. Braun, J.E., E. Huntzinger, and E. Izaurralde, The role of GW182 proteins in miRNA-mediated gene silencing. Adv Exp Med Biol, 2013. 768: 147-163.
31. Noland, C.L. and J.A. Doudna, Multiple sensors ensure guide strand selection in human RNAi pathways. RNA, 2013. 19(5): 639-648.
32. Takasaki, S., Methods for selecting effective siRNA target sequences using a variety of statistical and analytical techniques. Methods Mol Biol, 2013. 942: 17-55.
33. Filhol, O. et al., DSIR: Assessing the design of highly potent siRNA by testing a set of cancer-relevant target genes. PLoS One, 2012. 7(10): e48057.
34. Mysara, M., M. Elhefnawi, and J.M. Garibaldi, MysiRNA: Improving siRNA efficacy prediction using a machinelearning model combining multi-tools and whole stacking energy (DeltaG). J Biomed Inform, 2012. 45(3): 528-534.
35. Lu, Z.J. and D.H. Mathews, OligoWalk: An online siRNA design tool utilizing hybridization thermodynamics. Nucleic Acids Res, 2008. 36(Web Server issue): W104-W108.
36. Liu, Y. et al., Influence of mRNA features on siRNA interference efficacy. J Bioinform Comput Biol, 2013. 11(3): 1341004.
37. Sciabola, S. et al., Improved nucleic acid descriptors for siRNA efficacy prediction. Nucleic Acids Res, 2013. 41(3): 1383-1394.
38. Khvorova, A., A. Reynolds, and S.D. Jayasena, Functional siRNAs and miRNAs exhibit strand bias. Cell, 2003. 115(2): 209-216.
39. Reynolds, A. et al., Rational siRNA design for RNA interference. Nat Biotechnol, 2004. 22(3): 326-330.
40. Baranova, A. et al., An efficient algorithm for systematic analysis of nucleotide strings suitable for siRNA design. BMC Res Notes, 2011. 4: 168.
41. Boudreau, R.L. et al., siSPOTR: A tool for designing highly specific and potent siRNAs for human and mouse. Nucleic Acids Res, 2013. 41(1): e9.
42. Buehler, E. et al., siRNA off-target effects in genome-wide screens identify signaling pathway members. Sci Rep, 2012. 2: 428.
43. Das, S. et al., An siRNA designing tool with a unique functional off-target filtering approach. J Biomol Struct Dyn, 2012. 31(11): 1343-1357.
44. Wang, X. et al., Selection of hyperfunctional siRNAs with improved potency and specificity. Nucleic Acids Res, 2009. 37(22): e152.
45. Bramsen, J.B. et al., A screen of chemical modifications identifies position-specific modification by UNA to most potently reduce siRNA off-target effects. Nucleic Acids Res, 2010. 38(17): 5761-5773.
46. Engels, J.W., Gene silencing by chemically modified siRNAs. Nat Biotechnol, 2013. 30(3): 302-307.
47. Jackson, A.L. et al., Position-specific chemical modification of siRNAs reduces “off-target” transcript silencing. RNA, 2006. 12(7): 1197-1205.
48. Snead, N.M. et al., 5' Unlocked nucleic acid modification improves siRNA targeting. Mol Ther Nucleic Acids, 2013. 2: e103.
49. Zhang, J. et al., Modification of the siRNA passenger strand by 5-nitroindole dramatically reduces its off-target effects. Chembiochem, 2012. 13(13): 1940-1945.
50. Khan, A.A. et al., Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. Nat Biotechnol, 2009. 27(6): 549-555.
51. Liang, X.H., C.E. Hart, and S.T. Crooke, Transfection of siR-NAs can alter miRNA levels and trigger non-specific protein degradation in mammalian cells. Biochim Biophys Acta, 2013. 1829(5): 455-468.
52. Dalpke, A. and M. Helm, RNA mediated Toll-like receptor stimulation in health and disease. RNA Biol, 2012. 9(6): 828-842.
53. Olejniczak, M. et al., Recent advances in understanding of the immunological off-target effects of siRNA. Curr Gene Ther, 2011. 11(6): 532-543.
54. Whitehead, K.A. et al., Silencing or stimulation? siRNA delivery and the immune system. Annu Rev Chem Biomol Eng, 2011. 2: 77-96.
55. Goodchild, A. et al., Sequence determinants of innate immune activation by short interfering RNAs. BMC Immunol, 2009. 10: 40.
56. Jurk, M. et al., Immunostimulatory potential of silencing RNAs can be mediated by a non-uridine-rich toll-like receptor 7 motif. Nucleic Acid Ther, 2011. 21(3): 201-214.
57. Bramsen, J.B. and J. Kjems, Chemical modification of small interfering RNA. Methods Mol Biol, 2011. 721: 77-103.
58. Yu, H. et al., Recognition of nucleic acid ligands by toll-like receptors 7/8: Importance of chemical modification. Curr Med Chem, 2012. 19(9): 1365-1377.
59. Judge, A.D. et al., Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther, 2006. 13(3): 494-505.
60. Robbins, M. et al., 2'-O-methyl-modified RNAs act as TLR7 antagonists. Mol Ther, 2007. 15(9): 1663-1669.
61. Ameres, S.L., J. Martinez, and R. Schroeder, Molecular basis for target RNA recognition and cleavage by human RISC. Cell, 2007. 130(1): 101-112.
62. Haley, B. and P.D. Zamore, Kinetic analysis of the RNAi enzyme complex. Nat Struct Mol Biol, 2004. 11(7): 599-606.
63. Ma, J.B., K. Ye, and D.J. Patel, Structural basis for overhang-specific small interfering RNA recognition by the PAZ domain. Nature, 2004. 429(6989): 318-322.
64. Ma, J.B. et al., Structural basis for 5'-end-specific recognition of guide RNA by the A. fulgidus Piwi protein. Nature, 2005. 434(7033): 666-670.
65. Parker, J.S., S.M. Roe, and D. Barford, Structural insights into mRNA recognition from a PIWI domain-siRNA guide complex. Nature, 2005. 434(7033): 663-666.
66. Wang, H.-W. et al., Structural insights into RNA processing by the human RISC-loading complex. Nat Struct Mol Biol, 2009. 16(11): 1148-1153.
67. Wang, Y. et al., Nucleation, propagation and cleavage of target RNAs in Ago silencing complexes. Nature, 2009. 461(7265): 754-761.
68. Peacock, H. et al., Chemical modification of siRNA bases to probe and enhance RNA interference. J Org Chem, 2011. 76(18): 7295-7300.
69. Watts, J.K., G.F. Deleavey, and M.J. Damha, Chemically modified siRNA: Tools and applications. Drug Discov Today, 2008. 13(19-20): 842-855.
70. Crooke, S.T. and C.F. Bennett, Progress in antisense oligonucleotide therapeutics. Annu Rev Pharmacol Toxicol, 1996. 36: 107-129.
71. Uhlmann, E. and A. Peyman, Antisense oligonucleotides: A new therapeutic principle. Chem Rev, 1990. 90(4): 543-584.
72. Allerson, C.R. et al., Fully 2'-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. J Med Chem, 2005. 48(4): 901-904.
73. Prakash, T.P. et al., Positional effect of chemical modifications on short interference RNA activity in Mammalian cells. J Med Chem, 2005. 48(13): 4247-4253.
74. Elmen, J. et al., Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res, 2005. 33(1): 439-447.
75. Ui-Tei, K. et al., Functional dissection of siRNA sequence by systematic DNA substitution: Modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect. Nucleic Acids Res, 2008. 36(7): 2136-2151.
76. Manoharan, M. et al., Unique gene-silencing and structural properties of 2'-fluoro-modified siRNAs. Angew Chem Int Ed Engl, 2011. 50(10): 2284-2288.
77. Butora, G. et al., Nucleoside optimization for RNAi: A high-throughput platform. J Am Chem Soc, 2011. 133(42): 16766-16769.
78. Kenski, D.M. et al., siRNA-optimized modifications for enhanced in vivo activity. Mol Ther Nucleic Acids, 2012. 1: e5.
79. Schwarz, D.S. et al., Asymmetry in the assembly of the RNAi enzyme complex. Cell, 2003. 115(2): 199-208.
80. Laursen, M.B. et al., Utilization of unlocked nucleic acid (UNA) to enhance siRNA performance in vitro and in vivo. Mol Biosyst, 2010. 6(5): 862-870.
81. Vaish, N. et al., Improved specificity of gene silencing by siR-NAs containing unlocked nucleobase analogs. Nucleic Acids Res, 2011. 39(5): 1823-1832.
82. Deleavey, G.F. and M.J. Damha, Designing chemically modified oligonucleotides for targeted gene silencing. Chem Biol, 2012. 19(8): 937-954.
83. Hoshika, S., N. Minakawa, and A. Matsuda, RNA interference induced by siRNAs modified with 4'-thioribonucleo-sides. Nucleic Acids Symp Ser (Oxf), 2005. (49): 77-78.
84. Ittig, D. et al., Improving gene silencing of siRNAs via tricyclo-DNA modification. Artif DNA PNA XNA, 2010. 1(1): 9-16.
85. Yang, X. et al., Gene silencing activity of siRNA molecules containing phosphorodithioate substitutions. ACS Chem Biol, 2012. 7(7): 1214-1220.
86. Behlke, M.A., Chemical modification of siRNAs for in vivo use. Oligonucleotides, 2008. 18(4): 305-319.
87. Iwase, R., R. Kurokawa, and J. Ueno, Synthesis of modified double stranded RNAs containing duplex regions between amide-linked RNA and RNA at both ends and enhanced nuclease resistance. Nucleic Acids Symp Ser (Oxf), 2009. (53): 119-120.
88. Kubo, T. et al., Enhancement of gene silencing potency and nuclease stability by chemically modified duplex RNA. Nucleic Acids Symp Ser (Oxf), 2007. (51): 407-408.
89. Paris, C. et al., Conjugating phospho spermines to siRNAs for improved stability in serum, intracellular delivery and RNAi-mediated gene silencing. Mol Pharm, 2012. 9(12): 3464-3475.
90. Takahashi, M. et al., Intracellular stability of 2'-OMe-4'-thioribonucleoside modified siRNA leads to long-term RNAi effect. Nucleic Acids Res, 2012. 40(12): 5787-5793.
91. Vengut-Climent, E. et al., Synthesis, RNAi activity and nuclease-resistant properties of apolar carbohydrates siRNA conjugates. Bioorg Med Chem Lett, 2013. 23(14): 4048-4051.
92. Volkov, A.A. et al., Selective protection of nuclease-sensitive sites in siRNA prolongs silencing effect. Oligonucleotides, 2009. 19(2): 191-202.
93. Larsson, E., C. Sander, and D. Marks, mRNA turnover rate limits siRNA and microRNA efficacy. Mol Syst Biol, 2010. 6: 433.
94. Arvey, A. et al., Target mRNA abundance dilutes microRNA and siRNA activity. Mol Syst Biol, 2010. 6: 363.
95. Chan, C.Y. et al., A structural interpretation of the effect of GC-content on efficiency of RNA interference. BMC Bioinform, 2009. 10(Suppl. 1): S33.
96. Heale, B.S. et al., siRNA target site secondary structure predictions using local stable substructures. Nucleic Acids Res, 2005. 33(3): e30.
97. Mathews, D.H., Using OligoWalk to identify efficient siRNA sequences. Methods Mol Biol, 2010. 629: 109-121.
98. Gibbings, D.J. et al., Multivesicular bodies associate with components of miRNA effector complexes and modulate miRNA activity. Nat Cell Biol, 2009. 11(9): 1143-1149.
99. Reich, S.J. et al., Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis, 2003. 9: 210-216.
100. Dejneka, N.S. et al., Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes. Mol Vis, 2008. 14: 997-1005.
101. Shen, J. et al., Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther, 2006. 13(3): 225-234.
102. De Fougerolles, A.R. and J.M. Maraganore, Discovery and development of RNAi therapeutics, in Antisense Drug Technology, S.T. Crooke, ed. 2007, CRC Press: Boca Raton, FL.
103. Durcan, N., C. Murphy, and S.A. Cryan, Inhalable siRNA: Potential as a therapeutic agent in the lungs. Mol Pharm, 2008. 5(4): 559-566.
104. Lam, J.K., W. Liang, and H.K. Chan, Pulmonary delivery of therapeutic siRNA. Adv Drug Deliv Rev, 2012. 64(1): 1-15.
105. Bitko, V. et al., Inhibition of respiratory viruses by nasally administered siRNA. Nat Med, 2005. 11(1): 50-55.
106. Li, B.J. et al., Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat Med, 2005. 11(9): 944-951.
107. Zhang, X. et al., Small interfering RNA targeting heme oxygenase-1 enhances ischemia-reperfusion-induced lung apoptosis. J Biol Chem, 2004. 279(11): 10677-10684.
108. Senoo, T. et al., Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis. Thorax, 2010. 65(4): 334-340.
109. Miyamoto, S. et al., Intra-airway administration of small interfering RNA targeting plasminogen activator inhibitor-1 attenuates allergic asthma in mice. Am J Physiol Lung Cell Mol Physiol, 2011. 301(6): L908-L916.
110. Moschos, S.A. et al., Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjug Chem, 2007. 18(5): 1450-1459.
111. Moschos, S.A. et al., Uptake, efficacy, and systemic distribution of naked, inhaled short interfering RNA (siRNA) and locked nucleic acid (LNA) antisense. Mol Ther, 2011. 19(12): 2163-2168.
112. Gutbier, B. et al., RNAi-mediated suppression of constitutive pulmonary gene expression by small interfering RNA in mice. Pulm Pharmacol Ther, 2010. 23(4): 334-344.
113. Alvarez, R. et al., RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy. AntimicrobAgents Chemother, 2009. 53(9): 3952-3962.
114. Pardridge, W.M., Blood-brain barrier biology and methodology. J Neurovirol, 1999. 5(6): 556-569.
115. Yang, H., Nanoparticle-mediated brain-specific drug delivery, imaging, and diagnosis. Pharm Res, 2010. 27(9): 1759-1771.
116. Dorn, G. et al., siRNA relieves chronic neuropathic pain. Nucleic Acids Res, 2004. 32(5): e49.
117. Jean, A. et al., Anorexia induced by activation of serotonin 5-HT4 receptors is mediated by increases in CART in the nucleus accum-bens. Proc Natl Acad Sci USA, 2007. 104(41): 16335-16340.
118. Manrique, C. et al., Specific knock-down of GAD67 in the striatum using naked small interfering RNAs. J Biotechnol, 2009. 142(3-4): 185-192.
119. McCormack, A.L. et al., Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra. PLoS One, 2010. 5(8): e12122.
120. Querbes, W. et al., Direct CNS delivery of siRNA mediates robust silencing in oligodendrocytes. Oligonucleotides, 2009. 19(1): 23-30.
121. Stiles, D.K. et al., Widespread suppression of huntingtin with convection-enhanced delivery of siRNA. Exp Neurol, 2012. 233(1): 463-471.
122. Gonzalez-Gonzalez, E. et al., siRNA silencing of keratino-cyte-specific GFP expression in a transgenic mouse skin model. Gene Ther, 2009. 16(8): 963-972.
123. Ra, H. et al., Assessing delivery and quantifying efficacy of small interfering ribonucleic acid therapeutics in the skin using a dualaxis confocal microscope. J Biomed Opt, 2010. 15(3): 036027.
124. Hickerson, R.P. et al., Use of self-delivery siRNAs to inhibit gene expression in an organotypic pachyonychia congenita model. J Invest Dermatol, 2011. 131(5): 1037-1044.
125. Chong, R.H. et al., Gene silencing following siRNA delivery to skin via coated steel microneedles: In vitro and in vivo proof-of-concept. J Control Release, 2013. 166(3): 211-219.
126. Broderick, K.E. et al., Optimized in vivo transfer of small interfering RNA targeting dermal tissue using in vivo surface electroporation. Mol Ther Nucleic Acids, 2012. 1: e11.
127. De Souza, A.T. et al., Transcriptional and phenotypic comparisons of Ppara knockout and siRNA knockdown mice. Nucleic Acids Res, 2006. 34(16): 4486-4494.
128. Hamar, P. et al., Small interfering RNA targeting Fas protects mice against renal ischemia-reperfusion injury. Proc Natl Acad Sci USA, 2004. 101(41): 14883-14888.
129. Song, E. et al., RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med, 2003. 9(3): 347-351.
130. Soutschek, J. et al., Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature, 2004. 432(7014): 173-178.
131. Wolfrum, C. et al., Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol, 2007. 25(10): 1149-1157.
132. DiFiglia, M. et al., Therapeutic silencing of mutant hunting-tin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci USA, 2007. 104(43): 17204-17209.
133. Chen, Q. et al., Lipophilic sIRNAS mediate efficient gene silencing in oligodendrocytes with direct CNS delivery. J Control Release, 2010. 144: 227-232.
134. Saito, G., J.A. Swanson, and K.-D. Lee, Drug delivery strategy utilizing conjugation via reversible disulfide linkages: Role and site of cellular reducing activities. Adv Drug Deliv Rev, 2003. 55(2): 199-215.
135. Raouane, M. et al., Lipid conjugated oligonucleotides: A useful strategy for delivery. Bioconjug Chem, 2012. 23: 1091-1104.
136. Ashwell, G. and A.G. Morell, The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins. Adv Enzymol Relat Areas Mol Biol, 1974. 41(0): 99-128.
137. Pricer, W.E., Jr. et al., A membrane receptor protein for asialoglycoproteins. Methods Enzymol, 1974. 34: 688-691.
138. Biessen, E.A.L. et al., Synthesis of cluster galactosides with high affinity for the hepatic asialoglycoprotein receptor. J Med Chem, 1995. 38(9): 1538-1546.
139. Sliedregt, L.A. et al., Design and synthesis of novel amphiphilic dendritic galactosides for selective targeting of liposomes to the hepatic asialoglycoprotein receptor. J Med Chem, 1999. 42(4): 609-618.
140. Westerlind, U. et al., Ligands of the asialoglycoprotein receptor for targeted gene delivery, part 1: Synthesis of and binding studies with biotinylated cluster glycosides containing N-acetylgalactosamine. Glycoconj J, 2004. 21(5): 227-241.
141. Biessen, E.A. et al., Design of a targeted peptide nucleic acid prodrug to inhibit hepatic human microsomal triglyceride transfer protein expression in hepatocytes. Bioconjug Chem, 2002. 13(2): 295-302.
142. Biessen, E.A. et al., Targeted delivery of oligodeoxynucleo-tides to parenchymal liver cells in vivo. Biochem J, 1999. 340(Pt 3): 783-792.
143. Maier, M.A. et al., Synthesis of antisense oligonucleotides conjugated to a multivalent carbohydrate cluster for cellular targeting. Bioconjug Chem, 2003. 14(1): 18-29.
144. McNamara, J.O. et al., Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol, 2006. 24(8): 1005-1015.
145. Dassie, J.P. et al., Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol, 2009. 27(9): 839-849.
146. Kortylewski, M. et al., In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol, 2009. 27(10): 925-932.
147. Rozema, D.B. et al., Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci USA, August 7, 2007. 104(32): 12982-12987.
148. Wooddell, C.I. et al., Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol Ther, 2013. 21(5): 973-985.
149. Akhtar, S. and I. Benter, Toxicogenomics of non-viral drug delivery systems for RNAi: Potential impact on siRNA-medi-ated gene silencing activity and specificity. Adv Drug Deliv Rev, 2007. 59(2-3): 164-182.
150. Barros, S.A. and J.A. Gollob, Safety profile of RNAi nanomedicines. Adv Drug Deliv Rev, 2012. 64(15): 1730-1737.
151. Beyerle, A. et al., Inflammatory responses to pulmonary application of PEI-based siRNA nanocarriers in mice. Biomaterials, 2011. 32(33): 8694-8701.
152. Merkel, O.M. et al., Polymer-related off-target effects in nonviral siRNA delivery. Biomaterials, 2011. 32(9): 2388-2398.
153. Maeda, H., The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul, 2001. 41: 189-207.
154. Hu-Lieskovan, S. et al., Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing’s sarcoma. Cancer Res, 2005. 65(19): 8984-8992.
155. Heidel, J.D. et al., Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci USA, 2007. 104(14): 5715-5721.
156. Boussif, O. et al., A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine. Proc Natl Acad Sci USA, 1995. 92(16): 7297-7301.
157. Gunther, M. et al., Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung. Eur J Pharm Biopharm, 2011. 77(3): 438-449.
158. Hobel, S. and A. Aigner, Polyethylenimines for siRNA and miRNA delivery in vivo. Wiley Interdiscip Rev Nanomed Nanobiotechnol, September-October, 2013. 5(5): 484-501.
159. Nimesh, S., Polyethylenimine as a promising vector for targeted siRNA delivery. Curr Clin Pharmacol, 2012. 7(2): 121-130.
160. Alshamsan, A. et al., The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine. Biomaterials, 2010. 31(6): 1420-1428.
161. Liu, Y. et al., Targeting hypoxia-inducible factor-1alpha with Tf-PEI-shRNA complex via transferrin receptor-mediated endocytosis inhibits melanoma growth. Mol Ther, 2009. 17(2): 269-277.
162. Merkel, O.M. et al., Stability of siRNA polyplexes from poly(ethylenimine) and poly(ethylenimine)-g-poly(ethylene glycol) under in vivo conditions: Effects on pharmacokinetics and biodistribution measured by Fluorescence Fluctuation Spectroscopy and Single Photon Emission Computed Tomography (SPECT) imaging. J Control Release, 2009. 138(2): 148-159.
163. Zheng, M. et al., Enhancing in vivo circulation and siRNA delivery with biodegradable polyethylenimine-graft-polycaprolactone-block-poly(ethylene glycol) copolymers. Biomaterials, 2012. 33(27): 6551-6558.
164. Bolcato-Bellemin, A.L. et al., Sticky overhangs enhance siRNA-mediated gene silencing. Proc Natl Acad Sci USA, October 9, 2007. 104(41): 16050-5.
165. Kedinger, V. et al., Sticky siRNAs targeting survivin and cyclin B1 exert an antitumoral effect on melanoma subcutaneous xenografts and lung metastases. BMC Cancer, 2013. 13: 338.
166. Urban-Klein, B. et al., RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther, 2005. 12(5): 461-466.
167. Peer, D. et al., Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc Natl Acad Sci USA, 2007. 104(10): 4095-4100.
168. Kumar, P. et al., T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell, 2008. 134(4): 577-586.
169. Song, E. et al., Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol, 2005. 23(6): 709-717.
170. Peer, D. and J. Lieberman, Special delivery: Targeted therapy with small RNAs. Gene Ther, 2011. 18(12): 1127-1133.
171. Saranya, N. et al., Chitosan and its derivatives for gene delivery. Int J Biol Macromol, 2011. 48(2): 234-238.
172. Singha, K., R. Namgung, and W.J. Kim, Polymers in small-interfering RNA delivery. Nucleic Acid Ther, 2011. 21(3): 133-147.
173. Troiber, C. and E. Wagner, Nucleic acid carriers based on precise polymer conjugates. Bioconjug Chem, 2011.22(9): 1737-1752.
174. Wu, Z.W. et al., Recent progress in copolymer-mediated siRNA delivery. J Drug Target, 2012. 20(7): 551-560.
175. Lee, H. et al., Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nat Nanotechnol, 2012. 7(6): 389-393.
176. Lee, J.B. et al., Self-assembled RNA interference microsponges for efficient siRNA delivery. Nat Mater, 2012. 11(4): 316-322.
177. Kedmi, R., N. Ben-Arie, and D. Peer, The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials, 2010. 31(26): 6867-6875.
178. Fenske, D.B. and P.R. Cullis, Liposomal nanomedicines. Expert Opin Drug Deliv, 2008. 5(1): 25-44.
179. Gindy, M.E., A.M. Leone, and J.J. Cunningham, Challenges in the pharmaceutical development of lipid-based short interfering ribonucleic acid therapeutics. Expert Opin Drug Deliv, 2012. 9(2): 171-182.
180. Li, W. and F. Szoka, Jr.., Lipid-based nanoparticles for nucleic acid delivery. Pharm Res, 2007. 24(3): 438-449.
181. Schroeder, A. et al., Lipid-based nanotherapeutics for siRNA delivery. J Intern Med, 2010. 267(1): 9-21.
182. Wu, S.Y. and N.A. McMillan, Lipidic systems for in vivo siRNA delivery. AAPS J, 2009. 11(4): 639-652.
183. Buyens, K. et al., Liposome based systems for systemic siRNA delivery: Stability in blood sets the requirements for optimal carrier design. J Control Release, 2012. 158(3): 362-370.
184. Morrissey, D.V. et al., Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol, 2005. 23(8): 1002-1007.
185. Judge, A.D. et al., Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol, 2005. 23(4): 457-462.
186. Zimmermann, T.S. et al., RNAi-mediated gene silencing in non-human primates. Nature, 2006. 441(7089): 111-114.
187. Hafez, I.M., N. Maurer, and P.R. Cullis, On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther, 2001. 8(15): 1188-1196.
188. Zelphati, O. and F.C. Szoka, Jr.., Mechanism of oligonucleotide release from cationic liposomes. Proc Natl Acad Sci USA, 1996. 93(21): 11493-11498.
189. Jayaraman, M. et al., Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Ed Engl, 2012. 51(34): 8529-8533.
190. Semple, S.C. et al., Rational design of cationic lipids for siRNA delivery. Nat Biotechnol, 2010. 28(2): 172-176.
191. Akinc, A. et al., A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol, 2008. 26(5): 561-569.
192. Akinc, A. et al., Development of lipidoid-siRNA formulations for systemic delivery to the liver. Mol Ther, 2009. 17(5): 872-879.
193. Love, K.T. et al., Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci USA, 2010. 107(5): 1864-1869.
194. Basha, G. et al., Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells. Mol Ther, 2011. 19(12): 2186-2200.
195. Peer, D. et al., Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science, 2008. 319(5863): 627-630.
196. Adami, R.C. et al., An amino acid-based amphoteric liposomal delivery system for systemic administration of siRNA. Mol Ther, 2011. 19(6): 1141-1151.
197. Seth, S. et al., RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer. Mol Ther, 2011. 19(5): 928-935.
198. Santel, A. et al., A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther, 2006. 13(16): 1222-1234.
199. Santel, A. et al., RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy. Gene Ther, 2006. 13(18): 1360-1370.
200. Aleku, M. et al., Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res, 2008. 68(23): 9788-9798.
201. Akinc, A. et al., Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther, 2010. 18(7): 1357-1364.
202. Gilleron, J. et al., Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endo-somal escape. Nat Biotechnol, 2013. 31(7): 638-646.
203. Pei, Y. et al., Quantitative evaluation of siRNA delivery in vivo. RNA, 2010. 16(12): 2553-2563.
204. Wei, J. et al., RNA-induced silencing complex-bound small interfering RNA is a determinant of RNA interference-mediated gene silencing in mice. Mol Pharm, 2011. 79(6): 953-963.
205. Sahay, G. et al., Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat Biotechnol, 2013. 31(7): 653-658.
206. Maier, M.A. et al., Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol Ther, 2013. 21(8): 1570-1578.
207. Kleinman, M.E. et al., Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature, 2008. 452(7187): 591-597.
208. Jabs, D.A. and P.D. Griffiths, Fomivirsen for the treatment of cytomegalovirus retinitis. Am J Ophthalmol, 2002. 133(4): 552-556.
209. Gragoudas, E.S. et al., Pegaptanib for neovascular age-related macular degeneration. N Engl J Med, 2004. 351(27): 2805-2816.
210. Kaiser, P.K. et al., RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027. Am J Ophthalmol, 2010. 150(1): 33-39.e2.
211. Nguyen, Q.D. et al., Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study). Ophthalmology, 2012. 119(9): 1867-1873.
212. Nguyen, Q.D. et al., Dose-ranging evaluation of intravitreal siRNA PF-04523655 for diabetic macular edema (the DEGAS study). Invest Ophthalmol Vis Sci, 2012. 53(12): 7666-7674.
213. DeVincenzo, J. et al., Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res, 2008. 77(3): 225-231.
214. DeVincenzo, J. et al., A randomized, double-blind, placebocontrolled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci USA, 2010. 107(19): 8800-8805.
215. Zamora, M.R. et al., RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am J Respir Crit Care Med, 2011. 183(4): 531-538.
216. Leachman, S.A. et al., First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol Ther, 2010. 18(2): 442-446.
217. Macron, D., TransDerm’s RNAi-based skin disorder drug moves into one-patient clinical trial. RNAi News, 2008. 6(10): 1-3.
218. Tabernero, J. et al., First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov, 2013. 3(4): 406-417.
219. Gollob, J., Open-label extension study of the RNAi therapeutic ALN-VSP02 in cancer patients responding to therapy, in ASCO Annual Meeting. 2012: Chicago, IL.
220. Coelho, T. et al., Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med, 2013. 369(9): 819-829.
221. Adams, D. et al., Interim results from Phase II Trial of ALN-TTR02, a Novel RNAi therapeutic for the treatment of familial amyloidotic polyneuropathy, in Biennial Meeting of the Peripheral Nerve Society. 2013. St. Malo, France.
222. Fitzgerald, K. et al., Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: A randomised, single-blind, placebo-controlled, phase 1 trial. Lancet, published online October 3, 2013. 383(9911): 60-68.
223. Davis, M.E. et al., Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature, 2010. 464(7291): 1067-1070.
224. Opko Health, Inc. Open Label Study for the Evaluation of Tolerability of Five Dose Levels of Cand5. In: ClinicalTrials. gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2014 July 21]. Available from: http://clinicaltrials.gov/ct2/show/NCT00722384 NLM Identifier: NCT00722384.
225. Opko Health, Inc. Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular Degeneration. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2014 July 21]. Available from: http://clinicaltrials. gov/ct2/show/NCT00259753 NLM Identifier:NCT00259753.
226. Opko Health, Inc. Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat Diabetic Macular Edema. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2014 July 21]. Available from: http://clinicaltrials.gov/ct2/show/NCT00306904 NLM Identifier: NCT00306904.
227. Opko Health, Inc. Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (COBALT). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2014 July 21]. Available from: http://clinicaltrials.gov/ct2/show/NCT00499590 NLM Identifier: NCT00499590.
228. Allergan. A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2014 July 21]. Available from: http://clinicaltrials.gov/ct2/show/NCT00395057NLMIdentifier:NCT00395057.
229. Quark Pharmaceuticals. Study of PF-04523655 (REDD14NP) In Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (Wet AMD). In: ClinicalTrials.gov [Internet]. Bethesda (MD):National Library of Medicine (US). 2000- [cited 2014 July 21]. Available from: http://clinicaltrials.gov/ct2/show/NCT00725686 NLM Identifier:NCT00725686.
230. Quark Pharmaceuticals. PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME) (MATISSE). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2014 July 21]. Available from: http://clinicaltrials.gov/ct2/show/NCT01445899NLMIdentifier:NCT01445899.
231. Quark Pharmaceuticals. Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2014 July 21]. Available from: http://clinicaltrials.gov/ct2/show/NCT01064505NLMIdentifier:NCT01064505.
232. Quark Pharmaceuticals. “Quark Pharmaceuticals Reports Favorable Interim Results from Phase I Clinical Study of QPI-1007.” Accessed 2014 July 21. Available from: http://www.quarkpharma.com/QBI-EN/2012/clinicalstudyqpi-1007/
233. Alnylam Pharmaceuticals. Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2014 July 21]. Available from: http://clinicaltrials.gov/ct2/show/NCT01065935NLMIdentifier:NCT01065935.
234. Alnylam Pharmaceuticals. “Alnylam Presents Complete Results from Phase IIb Trial with ALN-RSV01, an Inhaled RNAi Therapeutic for the Treatment of Respiratory Syncytial Virus (RSV) Infection.” Accessed 2014 July 21. Available from: http://investors.alnylam.com/releasedetail.cfm?ReleaseID=734110.
235. News Medical. “Zabecor Pharmaceuticals initiates Phase II clinical trial of its Excellair asthma drug.” Accessed 2014 July 21. Available from: http://www.news-medical.net/news/20090914/Zabecor-Pharmaceuticals-initiates-Phase-II-clinical-trial-of-its-Excellair-asthma-drug.aspx.
236. Silenseed Ltd. Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV Phase I - Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Operable Adenocarcinoma of the Pancreas). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2014 July 21]. Available from: http://clinicaltrials.gov/show/NCT01188785NLMIdentifier:NCT01188785.
237. Silenseed Ltd. “siG12D-LODER Pancreatic Cancer.” Accessed 2014 July 21. Available from: http://silenseed. com/?page_id=2539
238. Silenseed Ltd. A Phase II Study of siG12D LODER in Combination With Chemotherapy in Patients With Unresectable Locally Advanced Pancreatic Cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2014 July 21]. Available from: http://clinicaltrials.gov/ct2/show/NCT01676259NLMIdentifier:NCT01676259.
239. Sylentis S.A. Tolerance and Effect on Intraocular Pressure After Administration of SYL040012. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2014 July 21]. Available from: http://clinicaltrials.gov/ct2/show/NCT00990743NLMIdentifier:NCT00990743.
240. Sylentis S.A. SYL040012. Tolerance and Effect on Intraocular Pressure in Subjects With Intraocular Pressure (IOP) >= 21 mm Hg. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2014 July 21]. Available from: http://clinicaltrials.gov/ct2/show/NCT01227291NLMIdentifier:NCT01227291.
241. Sylentis S.A. Dose Finding Clinical Trial With SYL040012 to Evaluate the Tolerability and Effect on Intraocular Pressure in Subjects With Ocular Hypertension or Open Angle Glaucoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2014 July 21]. Available from: http://clinicaltrials.gov/ct2/show/NCT01739244NLMIdentifier:NCT01739244.
242. RXi Pharmaceuticals. Evaluation of Safety, PK, and Preliminary Effects on Scar Formation of Multiple Intradermal Administrations of RXI-109. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2014 July 21]. Available from: http://clinicaltrials.gov/ct2/show/NCT01780077NLMIdentifier:NCT01780077.
243. RXi Pharmaceuticals. “RXi Pharmaceuticals Announces Positive Results in its First Double Blind Study in Healthy Volunteers with RXI-109.” Accessed 2014 July 21. Available from: http://www.rxipharma.com/2013/06/rxi-pharmaceu-ticals-announces-positive-results-in-its-first-double-blind-study-in-healthy-volunteers-with-rxi-109/
244. RXi Pharmaceuticals. Evaluation of the Safety, Pharmacokinetics, and Preliminary Effect on Scar Formation by RXI-109. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2014 July 21]. Available from: http://clinicaltrials.gov/ct2/show/NCT01640912NLMIdentifier:NCT01640912.
245. RXi Pharmaceuticals. “RXi Pharmaceuticals Announces Positive Data in Second Phase 1 Multi-Dose Study.” Accessed 2014 July 21. Available from: http://www.rxipharma. com/2013/07/rxi-pharmaceuticals-announces-positive-data-in-second-phase-1-multi-dose-study/
246. Alnylam Pharmaceuticals. Trial to Evaluate Safety and Tolerability of ALN-TTR02 in Transthyretin (TTR) Amyloidosis. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2014 July 21]. Available from: http://clinicaltrials.gov/ct2/show/NCT01617967NLMIdentifier:NCT01617967.
247. Alnylam Pharmaceuticals. “TTR Amyloidosis (FAP).” Accessed 2014 July 21. Available from: http://www.alnylam. com/product-pipeline/ttr-amyloidosis-fap/
248. Alnylam Pharmaceuticals. Trial to Evaluate Safety and Tolerability of ALN-PCS02 in Subjects With Elevated LDL-Cholesterol (LDL-C). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2014 July 21]. Available from: http://clinicaltrials.gov/ct2/show/NCT01437059NLMIdentifier:NCT01437059.
249. Tekmira Pharmaceuticals. Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Liposomal siRNA in Subjects With High Cholesterol. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2014 July 21]. Available from: http://clinicaltrials.gov/ct2/show/NCT00927459NLMIdentifier:NCT00927459.
250. Tekmira Pharmaceuticals. “Tekmira Pharmaceuticals Completes ApoB SNALP Phase 1 Clinical Trial.” Accessed 2014 July 21. Available from: http://investor.tekmirapharm. com/releasedetail.cfm?ReleaseID=534353.
251. Tekmira Pharmaceuticals. A Study to Determine Safety, Pharmacokinetics and Pharmacodynamics of Intravenous TKM 080301 in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2014 July 21]. Available from: http://clinicaltrials.gov/ct2/show/NCT01262235NLMIdentifier:NCT01262235.
252. Tekmira Pharmaceuticals. “Tekmira Presents Data From Its TKM-PLK1 Phase I Clinical Trial at American Association for Cancer Research (AACR) Meeting.” Accessed 2014 July 21. Available from: http://investor.tekmirapharm.com/releasedetail.cfm?ReleaseID=755333.
253. Tekmira Pharmaceuticals. Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study of Intravenous (IV) TKM-100201 Infusion. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2014 July 21]. Available from: http://clinicaltrials.gov/ct2/show/NCT01518881NLMIdentifier:NCT01518881.
254. Silence Therapeutics. Study With Atu027 in Patients With Advanced Solid Cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2014 July 21]. Available from: http://clinicaltrials.gov/ct2/show/NCT00938574NLMIdentifier:NCT00938574.
255. Silence Therapeutics. “Silence Therapeutics’ Atu027 Demonstrates Promising Antitumor Activity in Phase I Study Presented at ASCO.” Accessed 2014 July 21. Available from: http://silence-therapeutics.com/wp-content/uploads/2012/01/release_060611.pdf
256. Silence Therapeutics. Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2014 July 21]. Available from: http://clinicaltrials.gov/ct2/show/NCT01808638NLMIdentifier:NCT01808638.
257. Calando Pharmaceuticals. Safety Study of CALAA-01 to Treat Solid Tumor Cancers. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2014 July 21]. Available from: http://clinicaltrials.gov/ct2/show/NCT00689065NLMIdentifier:NCT00689065.
258. Quark Pharmaceuticals. A Dose Escalation and Safety Study of I5NP in Patients Undergoing Major Cardiovascular Surgery. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2014 July 21]. Available from: http://clinicaltrials.gov/ct2/show/NCT00554359NLMIdentifier:NCT00554359.
259. Quark Pharmaceuticals. I5NP for Prophylaxis of Delayed Graft Function in Kidney Transplantation. In: ClinicalTrials. gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2014 July 21]. Available from: http://clinicaltrials.gov/ct2/show/NCT00802347NLMIdentifier:NCT00802347.
260. Alnylam Pharmaceuticals. A Phase 1, Single- and MultiDose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-TTRSC in Healthy Volunteers. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2014 July 21]. Available from: http://clinicaltrials.gov/ct2/show/NCT01814839NLMIdentifier:NCT01814839.
261. Alnylam Pharmaceuticals. “Alnylam Reports Positive Clinical Results - with up to 94% Knockdown of Serum Transthyretin (TTR) - for ALN-TTRsc, a Subcutaneously Delivered RNAi Therapeutic for the Treatment of TTR-Mediated Amyloidosis (ATTR).” Accessed 2014 July 21. Available from: http:// phx.corporate-ir.net/phoenix.zhtml?c=148005&p=irol-newsArticle&ID=1856872&highlight